These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20818671)

  • 21. Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up.
    van Vugt JP; Piet KK; Vink LJ; Siesling S; Zwinderman AH; Middelkoop HA; Roos RA
    Mov Disord; 2004 Mar; 19(3):285-97. PubMed ID: 15022182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioural problems in Huntington's disease using the Problem Behaviours Assessment.
    Kingma EM; van Duijn E; Timman R; van der Mast RC; Roos RA
    Gen Hosp Psychiatry; 2008; 30(2):155-61. PubMed ID: 18291297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease.
    Dumas EM; Say MJ; Jones R; Labuschagne I; O'Regan AM; Hart EP; van den Bogaard SJ; Queller S; Justo D; Coleman A; Dar Santos RC; Dürr A; Leavitt BR; Tabrizi SJ; Roos RA; Stout JC
    J Huntingtons Dis; 2012; 1(1):97-106. PubMed ID: 25063192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease.
    Stüwe SH; Goetze O; Lukas C; Klotz P; Hoffmann R; Banasch M; Orth M; Schmidt WE; Gold R; Saft C
    Neurology; 2013 Feb; 80(8):743-6. PubMed ID: 23390182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saccades in presymptomatic and early stages of Huntington disease.
    Blekher T; Johnson SA; Marshall J; White K; Hui S; Weaver M; Gray J; Yee R; Stout JC; Beristain X; Wojcieszek J; Foroud T
    Neurology; 2006 Aug; 67(3):394-9. PubMed ID: 16855205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional decline in Huntington's disease.
    Feigin A; Kieburtz K; Bordwell K; Como P; Steinberg K; Sotack J; Zimmerman C; Hickey C; Orme C; Shoulson I
    Mov Disord; 1995 Mar; 10(2):211-4. PubMed ID: 7753064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coordination of fingertip forces during precision grip in premanifest Huntington's disease.
    Rao AK; Gordon AM; Marder KS
    Mov Disord; 2011 Apr; 26(5):862-9. PubMed ID: 21394785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motor outcome measures in Huntington disease clinical trials.
    Reilmann R; Schubert R
    Handb Clin Neurol; 2017; 144():209-225. PubMed ID: 28947119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease.
    Hart EP; Dumas EM; Schoonderbeek A; Wolthuis SC; van Zwet EW; Roos RA
    Mov Disord; 2014 Mar; 29(3):320-6. PubMed ID: 24500841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study.
    Youssov K; Dolbeau G; Maison P; Boissé MF; Cleret de Langavant L; Roos RA; Bachoud-Lévi AC
    Mov Disord; 2013 Dec; 28(14):1995-2001. PubMed ID: 24123464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Motor cortical excitability studied with repetitive transcranial magnetic stimulation in patients with Huntington's disease.
    Lorenzano C; Dinapoli L; Gilio F; Suppa A; Bagnato S; Currà A; Inghilleri M; Berardelli A
    Clin Neurophysiol; 2006 Aug; 117(8):1677-81. PubMed ID: 16793338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study.
    Beckmann H; Bohlen S; Saft C; Hoffmann R; Gerss J; Muratori L; Ringelstein EB; Landwehrmeyer GB; Reilmann R
    Gait Posture; 2018 May; 62():451-457. PubMed ID: 29660633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease.
    Hausdorff JM; Cudkowicz ME; Firtion R; Wei JY; Goldberger AL
    Mov Disord; 1998 May; 13(3):428-37. PubMed ID: 9613733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of quantitative oculometry in the assessment of Huntington's disease.
    Ali FR; Michell AW; Barker RA; Carpenter RH
    Exp Brain Res; 2006 Feb; 169(2):237-45. PubMed ID: 16273398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into gait disorders: walking variability using phase plot analysis, Huntington's disease.
    Collett J; Esser P; Khalil H; Busse M; Quinn L; DeBono K; Rosser A; Nemeth AH; Dawes H
    Gait Posture; 2014 Sep; 40(4):694-700. PubMed ID: 25172806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cortical inhibitory deficits in premanifest and early Huntington's disease.
    Philpott AL; Cummins TDR; Bailey NW; Churchyard A; Fitzgerald PB; Georgiou-Karistianis N
    Behav Brain Res; 2016 Jan; 296():311-317. PubMed ID: 26416671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tapping linked to function and structure in premanifest and symptomatic Huntington disease.
    Bechtel N; Scahill RI; Rosas HD; Acharya T; van den Bogaard SJ; Jauffret C; Say MJ; Sturrock A; Johnson H; Onorato CE; Salat DH; Durr A; Leavitt BR; Roos RA; Landwehrmeyer GB; Langbehn DR; Stout JC; Tabrizi SJ; Reilmann R
    Neurology; 2010 Dec; 75(24):2150-60. PubMed ID: 21068430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease.
    Aziz NA; Anguelova GV; Marinus J; Lammers GJ; Roos RA
    Parkinsonism Relat Disord; 2010 Jun; 16(5):345-50. PubMed ID: 20236854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal resting state fMRI analysis in healthy controls and premanifest Huntington's disease gene carriers: a three-year follow-up study.
    Odish OF; van den Berg-Huysmans AA; van den Bogaard SJ; Dumas EM; Hart EP; Rombouts SA; van der Grond J; Roos RA;
    Hum Brain Mapp; 2015 Jan; 36(1):110-9. PubMed ID: 25139578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.